TLX — Telix Pharmaceuticals Limited stock price, charts and financials

Latest market price

11.79

+0.27+2.34%

Overview Short InterestFilings

TLXQT53Telix Pharmaceuticals Limited·NASDAQ

Overview Short InterestFilings

11.79+2.34%

Loading chart...

Signal & projected range

QT Score upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CPRX+0.00%$31.49 LEGN-0.43%$20.66 DNLI+0.68%$25.00 ADPT+2.09%$25.45 VKTX+0.53%$34.44 RCUS+0.35%$28.72 PRTC+4.51%$17.38 IDYA-0.76%$36.74

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.02	Insider Own	6.13%	Shs Outstand	338.78M	Perf Week	16.48%

Market Cap	3.88B	Forward P/E	120.90	EPS next Y	0.10	Insider Trans	0.33%	Shs Float	272.81M	Perf Month	-2.21%

Enterprise Value	4.22B	PEG	4.15	EPS next Q	0.03	Inst Own	-	Short Float	0.11%	Perf Quarter	8.07%

Income	-7.76M	P/S	4.48	EPS this Y	287.41%	Inst Trans	-	Short Ratio	1.69	Perf Half Y	65.52%

Sales	865.43M	P/B	8.81	EPS next Y	154.22%	ROA	-0.61%	Short Interest	297.14K	Perf YTD	53.81%

Book/sh	-	P/C	-	EPS next 5Y	115.36%	ROE	-1.72%	52W High	12.90 -8.57%	Perf Year	-3.76%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	1.77%	52W Low	6.43 83.44%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	161.02	Sales past 3/5Y	91.38% 186.94%	Gross Margin	50.76%	Volatility	2.05% 2.35%	Perf 5Y	-

Dividend TTM	-	EV/Sales	4.88	EPS Y/Y TTM	-121.66%	Oper. Margin	2.11%	ATR (14)	0.39	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	52.22%	Profit Margin	-0.89%	RSI (14)	63.67	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	1.43	EPS Q/Q	-	SMA20	9.63%	Beta	1.06	Target Price	18.00

Payout	0.00%	Debt/Eq	1.12	Sales Q/Q	122.40%	SMA50	10.97%	Rel Volume	1.31	Prev Close	11.52

Employees	1,152	LT Debt/Eq	1.08	Earnings	Aug 20	SMA200	23.85%	Avg Volume	161.66K	Price	11.79

IPO Date	Nov 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.66% 25507.52%	Net Debt/EBITDA	13.13	Volume	212,038	Change	2.34%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-16-26	Reiterated	RBC Capital		$17 → $18
Dec-15-25	Initiated	RBC Capital	Sector Perform	$17
Sep-23-25	Reiterated	UBS	Buy	$20
Sep-10-25	Reiterated	HC Wainwright & Co.	Buy	$20
Aug-28-25	Downgrade	JP Morgan	Overweight → Neutral

Latest News

Aug-05-26

Aug-05-2607:00AM

Telix to Host R&D Day in New York City on September 22, 2026globenewswire.com

Jul-31-26

Jul-31-2609:20AM

Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moatseekingalpha.com

Jul-30-26

Jul-30-2606:37PM

Telix H1 2026 Results: Investor Webcast Notificationglobenewswire.com

Jul-22-26

Jul-22-2610:56AM

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?zacks.com

Jul-21-26

Jul-21-2605:03PM

Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic ApproachBenzinga

05:00PM

TLX591-Tx ProstACT SELECT Study Published in Cancers Journalglobenewswire.com

Jul-20-26

Jul-20-2607:31PM

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progressglobenewswire.com

05:14PM

Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON StudyBenzinga

05:00PM

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancerglobenewswire.com

Jul-15-26

Jul-15-2604:20PM

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancerglobenewswire.com

Jul-07-26

Jul-07-2602:25PM

Citigroup Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $22Benzinga

Jul-01-26

Jul-01-2609:31PM

FDA Alignment to Advance ProstACT Global Phase 3 Trialglobenewswire.com

Jun-30-26

Jun-30-2601:32AM

Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcriptseekingalpha.com

Jun-22-26

Jun-22-2609:40PM

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic DirectionsYahoo

Jun-17-26

Jun-17-2607:38PM

Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research PartnershipYahoo

Company

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	787	778	517	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	387	365	180	—	—	—	—	—	—
Gross Profit	400	413	336	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	214	230	137	—	—	—	—	—	—
Research and Development	167	166	80	—	—	—	—	—	—
Other Operating Expense	3	0	65	—	—	—	—	—	—
Operating Income	16	17	54	—	—	—	—	—	—
Interest Expense	11	36	14	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-11	13	-3	—	—	—	—	—	—
Net Income Before Taxes	-5	-5	37	—	—	—	—	—	—
Income Taxes	6	2	4	—	—	—	—	—	—
Consolidated Net Income	-7	-7	33	—	—	—	—	—	—
Net Income From Continuing Operations	-7	-7	33	—	—	—	—	—	—
Net Income	-7	-7	33	—	—	—	—	—	—
EPS (Recurring)	-0.02	-0.02	0.10	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.02	-0.02	0.10	—	—	—	—	—	—
EPS (Diluted)	-0.02	-0.02	0.09	—	—	—	—	—	—
EBITDA	25	52	65	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	166.75	—	—	—	—	—	—
Price To Sales Ratio	5.08	3.25	9.86	—	—	—	—	—	—
Gross Margin	50.83	53.08	64.99	—	—	—	—	—	—
Operating Margin	2.03	2.19	10.44	—	—	—	—	—	—
Net Margin	-0.89	-0.90	6.38	—	—	—	—	—	—
Shares Outstanding	339	338	331	—	—	—	—	—	—
Market Capitalization	3,997	2,532	5,097	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Behrenbruch Christian	MD & Group CEO	Apr 29 '26	Buy	14.87	33,435	497,178	20,742,935	May 06
Behrenbruch Christian	MD & Group CEO	Apr 28 '26	Buy	14.48	34,500	499,560	20,709,500	May 06
Smith Darren Charlton	Group Chief Financial Officer	Mar 29 '26	Option Exercise	0.00	1,111	0	11,921	Apr 01
BRANDT RICHARD PAUL	director, 10 percent owner:	Sep 11 '07	Option Exercise	4.03	2,500	10,063	5,160	Sep 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.